PR
Therapeutic Areas
Cantargia Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Nadunolimab (CAN04) | Pancreatic Cancer (1L) | Phase II/III |
| CAN10 | Inflammatory/Autoimmune Diseases | Phase I (Completed) |
| CAN14 | Inflammatory/Autoimmune Diseases | Preclinical |
Leadership Team at Cantargia
HH
Hilde H. Steineger
Chief Executive Officer (CEO)
DL
David Liberg
Chief Scientific Officer (CSO)
TB
Ton Berkien
Chief Business Officer (CBO)
MP
Magnus Persson
Chairman of the Board
AM
Anders Martin-Löf
Board Member
FB
Flavia Borellini
Board Member
DM
Damian Marron
Board Member
JS
Jenny Sundqvist
Board Member